Total Clarity Wealth Management’s United Therapeutics UTHR Stock Holding History

Total Clarity Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,160	Closed	-$266K	–	289
2024 Q1	$266K	Sell	1,160 -4	-0.3%	-$903	0.09%	218
2023 Q4	$256K	Sell	1,164 -5	-0.4%	-$1.15K	0.1%	197
2023 Q3	$264K	Sell	1,169 -37	-3%	-$8.52K	0.13%	175
2023 Q2	$266K	Buy	+1,206	New	+$267K	0.13%	170
2022 Q3	–	Sell	-47	Closed	-$11K	–	941
2022 Q2	$11K	Buy	+47	New	+$9.55K	0.01%	651
2022 Q1	–	Sell	-47	Closed	-$10K	–	880
2021 Q4	$10K	Hold	47	–	–	﹤0.01%	705
2021 Q3	$9K	Buy	+47	New	+$9.26K	﹤0.01%	715
2021 Q2	–	Sell	-47	Closed	-$8K	–	719
2021 Q1	$8K	Buy	+47	New	+$7.84K	﹤0.01%	605
2020 Q1	–	Sell	-47	Closed	-$4K	–	592
2019 Q4	$4K	Buy	+47	New	+$4.14K	﹤0.01%	618

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Total Clarity Wealth Management's UTHR Position: Q2 2024 in Review

Total Clarity Wealth Management sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 1,160 shares — an estimated $266K sold.

Total Clarity Wealth Management first reported a position in UTHR in Q4 2019 and held it in 9 quarters. The position peaked at $266K in Q1 2024. 568 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

Total Clarity Wealth Management reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
Total Clarity Wealth Management sold 1,160 United Therapeutics shares in Q2 2024, an estimated $266K.
Total Clarity Wealth Management first reported a position in United Therapeutics in Q4 2019 and held it in 9 quarters.
Total Clarity Wealth Management's United Therapeutics position peaked at $266K in Q1 2024.
568 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Total Clarity Wealth Management's 13F filing for Q2 2024, filed 9 Aug 2024.